Loading organizations...

§ Private Profile · Palo Alto, CA, USA
Precision medicine biotech developing precision therapies, diagnostics, and AI for immune-driven critical and chronic illnesses.
Based in Palo Alto, California, Endpoint Health is a biotechnology company that develops precision-first therapies and companion diagnostics for immune-driven critical and chronic illnesses, including sepsis, acute respiratory distress syndrome, inflammatory bowel disease, and rheumatoid arthritis. The firm utilizes artificial intelligence and biomarker data to identify high-responder patient subtypes, aiming to accelerate the clinical advancement of targeted immunology drugs. Operating with a team of 23 employees, the company has established clinical partnerships with over 60 hospitals, featuring major medical institutions like Cleveland Clinic and Vanderbilt. Operating at the Series A stage, the business has raised $52 million in total funding and achieved a valuation exceeding $150 million, supported by prominent investors such as Y Combinator, Mayfield Fund, and AME Cloud Ventures. Endpoint Health was founded in 2018 by Jason Springs, Diego Rey, and Leonardo Teixeira.
Endpoint Health has raised $88.0M across 3 funding rounds.
Endpoint Health has raised $88.0M in total across 3 funding rounds.
Endpoint Health has raised $88.0M in total across 3 funding rounds.
Endpoint Health's investors include Adjuvant Capital, Anzu Partners, BoxOne Ventures, Domain Associates, Vensana Capital, Alix Ventures, AME Cloud Ventures, Boom Capital, Charlie Petty, HCX Ventures, Humboldt Fund, Mayfield.
Endpoint Health is a precision-first therapeutics company focused on developing targeted therapies and companion diagnostics for immune-mediated chronic and acute diseases, including critical illnesses like sepsis and acute respiratory distress syndrome (ARDS). Leveraging proprietary artificial intelligence (AI) platforms, Endpoint Health aims to personalize treatment by matching therapies to individual patient biology, improving outcomes beyond traditional one-size-fits-all approaches. Their products serve healthcare providers, clinicians, and researchers managing complex immune-driven conditions, addressing the unmet need for precision immunotherapy in critical care and chronic inflammatory diseases[1][2][3][4].
Founded in the mid-2010s, Endpoint Health emerged from a vision to rethink biopharma by moving away from molecule-first drug development toward a precision-first model. The company was co-founded by experts in biotechnology and AI-driven healthcare, motivated by the question of what a modern biopharma company would look like if built from scratch today. Early traction came from developing a precision medicine ecosystem that integrates therapeutics with diagnostics, validated through clinical trials and partnerships focused on critical illnesses. The team spans multiple continents, reflecting a global approach to innovation[1][4][6][7].
Endpoint Health rides the growing trend of precision medicine and immunotherapy, particularly in the critical illness segment where treatment personalization can dramatically improve survival and recovery rates. The timing is crucial as advances in AI, biomarker testing, and immunology converge to enable targeted therapies that were previously unattainable. Market forces such as rising chronic immune diseases, demand for better clinical outcomes, and healthcare cost optimization favor Endpoint Health’s approach. By integrating diagnostics with therapeutics, the company influences the broader ecosystem by setting new standards for personalized treatment and fostering collaboration between biotech, AI, and clinical care sectors[2][3][4].
Looking ahead, Endpoint Health is poised to expand its precision medicine ecosystem, potentially broadening its therapeutic pipeline and deepening partnerships with healthcare systems globally. Trends such as AI-driven drug discovery, real-time biomarker monitoring, and adaptive immunotherapies will shape their trajectory. Their influence may grow as they validate and commercialize targeted therapies that reduce treatment variability and improve patient outcomes in critical and chronic immune diseases. Endpoint Health’s vision of a world where every patient receives the best treatment for their unique biology positions them as a transformative player in biopharma’s future[3][4][6].
Endpoint Health has raised $88.0M across 3 funding rounds. Most recently, it raised $52.0M Series A in June 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2022 | $52M Series A | — | Adjuvant Capital, Anzu Partners, BoxOne Ventures, Domain Associates, Vensana Capital, Alix Ventures, AME Cloud Ventures, Boom Capital, Charlie Petty, HCX Ventures, Humboldt Fund, Mayfield, The Venture Collective, Wireframe Ventures, Yaya Capital | Announced |
| Jul 13, 2020 | $24M Debt Financing | — | AME Cloud Ventures, Ursheet Parikh, Wireframe Ventures, Y Combinator | Announced |
| Jul 1, 2020 | $12M Series U | — | Andreessen Horowitz, AngelList, Buckley Ventures, Dcvc (data Collective), Divergence Ventures, Founder Collective, Future Ventures, Greylock, Helium 3 Ventures, Liquid 2 Ventures, Quiet Capital, Rivet Ventures, Scale Asia Ventures, Solana Ventures, Unruly Capital, UpHonest Capital, Y Combinator, Ylem, Arash Ferdowsi, Aston Motes, Augusto Marietti, Dylan Field, Howie LIU, Immad Akhund, Jack Smith, Matt Bellamy, Paul McKellar, Sumon Sadhu | Announced |